Hospitalization as an Opportunity for Acute Heart Failure GDMT

Hospitalization provides a critical window to optimize evidence-based therapy in cardiovascular medicine. In contemporary clinical practice, the initiation of acute heart failure GDMT following clinical stabilization significantly reduces cardiovascular mortality and recurrent admissions. However, clinical inertia frequently delays guideline-directed medical therapy until outpatient follow-up. This delay leaves vulnerable patients completely unprotected during the high-risk vulnerable phase following discharge. To evaluate real-world feasibility, investigators analyzed patient records from the VancOuver CoastAL Acute Heart Failure Audit, widely recognized as the VOCAL-AHF study. This comprehensive registry systematically assessed medical therapy eligibility across distinct left ventricular ejection fraction categories in an acute inpatient setting. Historically, clinicians assumed that significant renal dysfunction, advanced age, or mild hemodynamic instability strictly prevented guideline implementation in acute care wards. Consequently, many physicians hesitated to introduce multiple disease-modifying agents simultaneously before discharge. Nevertheless, contemporary data indicate that early hemodynamic stabilization permits rapid and safe medical titration under close clinical monitoring. Therefore, establishing comprehensive treatment regimens before discharge represents an indispensable clinical priority for hospital teams. By transforming an acute decompensation into a proactive opportunity, clinical teams can improve long-term functional status and survival across diverse patient populations.

Phenotypic Distribution and Quadruple Therapy Eligibility in HFrEF

The VOCAL-AHF registry evaluated 1,587 consecutive hospitalized patients presenting with acute heart failure across urban medical centers. Among this contemporary cohort, 782 patients had reduced ejection fraction, 132 individuals had mildly reduced ejection fraction, and 673 patients had preserved ejection fraction. The mean patient age was 73 years, and men comprised 58 percent of the study population. In patients with reduced ejection fraction, eligibility for foundational pharmacological pillars remained remarkably high. Specifically, 89.6 percent of these patients met society guideline criteria for beta-blocker therapy. Furthermore, 82.2 percent qualified for sodium-glucose cotransporter-2 inhibitors, and 73.8 percent demonstrated clear eligibility for mineralocorticoid receptor antagonists. Additionally, 64.4 percent fulfilled clinical indications for angiotensin receptor-neprilysin inhibitors. Most importantly, 64.5 percent of individuals with reduced ejection fraction qualified for complete quadruple medical therapy before hospital discharge. These robust findings demonstrate that physiological contraindications rarely exclude patients from life-saving treatments in real-world acute settings. Consequently, hospital physicians should aggressively initiate all four foundational classes rather than deferring therapeutic decisions to subsequent outpatient appointments. Early initiation solidifies therapeutic momentum and enhances long-term adherence.

Expanding Inpatient GDMT to Non-Reduced Ejection Fraction

Historically, pharmacotherapy for heart failure with preserved or mildly reduced ejection fraction offered very limited clinical benefit. However, contemporary cardiovascular trials have dramatically transformed clinical care for non-reduced ejection fraction phenotypes in recent years. Within the VOCAL-AHF registry, patients with mildly reduced ejection fraction showed impressive candidate rates for evidence-based drugs. Specifically, 66.7 percent qualified for sodium-glucose cotransporter-2 inhibitors, 60.6 percent were eligible for steroidal mineralocorticoid receptor antagonists, and 56.8 percent met criteria for angiotensin receptor-neprilysin inhibitors. Overall, 56 percent of patients with mildly reduced ejection fraction were suitable candidates for concurrent triple therapy before discharge. Similarly, patients presenting with preserved ejection fraction showed extensive therapeutic eligibility during inpatient admission. In fact, 66.6 percent of all patients with non-reduced ejection fraction qualified for dual therapy combining sodium-glucose cotransporter-2 inhibitors with finerenone. Therefore, modern disease-modifying regimens can actively target non-reduced ejection fraction during index admissions. Hospitalists can systematically deploy these proven therapies to curtail worsening congestion and mitigate hospital readmission rates across all ejection fraction subsets.

The Emerging Role of Non-Steroidal MRAs in Inpatient Care

Non-steroidal mineralocorticoid receptor antagonists represent an exciting paradigm shift in managing heart failure across preserved ejection fraction phenotypes. The VOCAL-AHF audit examined patient eligibility for finerenone using two distinct assessment frameworks. When applying pragmatic clinical criteria, investigators observed that 62.1 percent of patients with mildly reduced ejection fraction qualified for finerenone. Under strict clinical trial criteria, 34.1 percent met eligibility. Correspondingly, 67.4 percent of patients with preserved ejection fraction met clinical indications, while 37.1 percent met strict trial criteria. This discrepancy illustrates that broad clinical eligibility exists beyond stringent clinical trial enrollment boundaries in routine practice. Furthermore, finerenone demonstrates favorable cardiorenal outcomes with a manageable risk profile for hyperkalemia compared to traditional steroidal antagonists. Consequently, initiating non-steroidal mineralocorticoid receptor antagonists alongside sodium-glucose cotransporter-2 inhibitors provides powerful synergistic organ protection for vulnerable patients. Clinicians must actively evaluate serum potassium and estimated glomerular filtration rate during hospitalization. By establishing these essential baseline parameters, medical teams can prescribe finerenone safely and confidently to optimize outcomes.

Overcoming Therapeutic Inertia in Indian and Global Practice

Translating registry findings into routine bedside practice requires a proactive cultural shift among acute care clinicians globally. In India and across diverse international healthcare systems, heart failure imposes an enormous epidemiological burden and high readmission rates. Frequently, clinicians express unwarranted apprehension regarding worsening renal function or transient hypotension during initial drug titration. However, randomized clinical trials demonstrate that early inpatient initiation yields rapid clinical stability and sustained prognostic benefits. Furthermore, patients discharged without guideline-directed medications seldom receive therapy intensification in busy ambulatory clinics. Therefore, multidisciplinary cardiac teams must establish structured inpatient order sets and protocolized discharge planning to overcome systemic delays. Prior to hospital discharge, teams should confirm patient euvolemia, verify stable renal function, and initiate low starting doses. In addition, providing structured patient education regarding medication adherence and symptom tracking promotes long-term treatment persistence. By seizing the hospital admission window, healthcare providers can dismantle therapeutic inertia and significantly optimize long-term clinical trajectories for every heart failure patient.

Frequently Asked Questions

Why should clinicians initiate acute heart failure GDMT before hospital discharge?

Starting guideline-directed medical therapy during hospitalization ensures immediate cardioprotection during the vulnerable post-discharge period. Historically, deferring prescriptions to outpatient clinics leads to substantial therapeutic inertia and prolonged treatment gaps. Furthermore, initiating therapies under inpatient supervision allows physicians to assess safety, adjust dosages, and monitor hemodynamic stability effectively. Consequently, in-hospital initiation significantly reduces short-term mortality and prevents avoidable heart failure readmissions.

How does GDMT eligibility differ between HFrEF and non-reduced ejection fraction phenotypes?

Patients with reduced ejection fraction demonstrate widespread eligibility for foundational quadruple therapy, including beta-blockers, SGLT2 inhibitors, MRAs, and ARNIs. In contrast, patients with non-reduced ejection fraction historically had fewer treatment options. However, contemporary evidence confirms that over sixty percent of patients with non-reduced ejection fraction now qualify for disease-modifying regimens, particularly SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists like finerenone.

What role does finerenone play in patients hospitalized with HFmrEF or HFpEF?

Finerenone provides targeted mineralocorticoid receptor blockade with reduced hyperkalemia risk compared to classical steroidal agents. Clinical analyses demonstrate that over sixty percent of patients with non-reduced ejection fraction meet clinical criteria for finerenone initiation. Furthermore, combining finerenone with sodium-glucose cotransporter-2 inhibitors offers complementary cardiorenal protection. When physicians verify baseline renal parameters and serum potassium, they can safely initiate this dual therapy prior to discharge.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Qualified healthcare professionals should exercise their independent clinical judgment when interpreting and applying this information. Clinical circumstances and patient presentations vary significantly. Healthcare providers must remain updated with evolving medical research and regulatory standards. Refer to the latest local and national guidelines for clinical practice.

References

1. Hui M et al. Assessment of eligibility for evidence-based pharmacological therapies in acute heart failure across heart failure with reduced and non-reduced ejection fraction. Eur J Intern Med. 2026 Nov 12. doi: undefined. PMID: 43020749.


2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.


3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421.